All issues

Issue guide · Reviewed

Reproductive Policy

Reproductive policy includes abortion, contraception, fertility care, and support around pregnancy. States set many access rules, while federal law affects medication, funding, insurance, and cross-state disputes.

Reproductive Policy by the numbers

Reported abortions
613,383CDC reporting areas · 2022 historical baselineCDC · Abortion Surveillance, United States, 2022
Reporting areas
48Voluntary CDC reporting · 2022CDC · Abortion Surveillance, United States, 2022
Reported abortion rate
11.2 / 1,000Women ages 15–44 · 47 consistent reporting areasCDC · Abortion Surveillance, United States, 2022

Reported rates before and during the Dobbs year

Abortions per 1,000 women ages 15–44 · Bars start at zero

Reported rates before and during the Dobbs year2021: 11.6; 2022: 11.2. Abortions per 1,000 women ages 15–44. 202111.6202211.2
Historical surveillance, not a current national count. Rates cover the same 47 reporting areas; California, Maryland, New Hampshire, New Jersey, and D.C. are excluded from this consistent-area series. The change alone does not establish the effect of Dobbs.
CDC · Abortion Surveillance, United States, 2022
View the data
Abortions per 1,000 women ages 15–44
MeasureValue
202111.6
202211.2

What needs solving

Location affects practical access

Travel, appointment availability, cost, and state restrictions can affect access even when a service is lawful somewhere. A national legal label does not describe every patient’s situation.

Supreme Court · Dobbs docket

Medication and funding are separate levers

FDA regulation, prescribing rules, insurance coverage, and public funding each affect care. Approval of a drug does not decide every question about where it may be used.

FDA · mifepristone information

Data can lag policy

CDC’s voluntary reporting omits some jurisdictions and appears after the reference year. The 2022 figures should not be presented as a complete measure of care after subsequent legal changes.

CDC · Abortion Surveillance, United States, 2022

The policy debate

Federal protection or state control

Establish a federal access floor, enact federal restrictions, or leave more decisions to states. The debate includes constitutional authority and the scope of exceptions.

Coverage and public funding

Expand insurance and public support or restrict funding based on objections to particular services. Distinguish contraception, fertility treatment, and abortion.

Medication and interstate care

Set rules for remote prescribing, mailing, and cross-state enforcement. Patient privacy and conflicting state laws complicate implementation.

Federal legislation and rules

Selected laws, proposals, and implementation—not a complete legislative inventory.

How to read this tracker
  1. ProposalA bill’s text states what its sponsors want to change.
  2. EnactmentBoth chambers pass matching text; presidential approval or a veto override makes law.
  3. ImplementationAgencies administer the law within their authority. Courts may review legal challenges.

Agency rules follow a separate process. A proposed rule is not a final rule, and a temporary court order is not a final merits decision.

Introduced text · June 2025Women’s Health Protection Act · H.R. 12

Would establish federal protections for abortion access and restrict specified governmental limitations. It is a proposal, not an enacted nationwide access guarantee.

Women’s Health Protection Act · H.R. 12
Federal grant frameworkTitle X family planning

Supports family-planning services through grants. Program funding and participation rules are separate from FDA drug approval and state abortion law.

HHS · Title X family planning program
FDA approval and safety informationMifepristone regulation

FDA’s product information and program requirements are the primary federal source for medication regulation. State access restrictions and litigation require separate analysis.

FDA · mifepristone information

Federal courts

Decided · Jun 13, 2024

FDA v. Alliance for Hippocratic Medicine · No. 23-235

The Court held that the plaintiffs lacked standing to challenge FDA’s actions concerning mifepristone in that case.

Why it matters. The decision did not decide the merits of FDA’s safety judgment or resolve every later challenge to medication abortion.

Supreme Court · FDA v. Alliance docket

Decided · Jun 24, 2022

Dobbs v. Jackson Women’s Health Organization · No. 19-1392

The Court overruled Roe and Casey, holding that the federal Constitution does not confer a right to abortion.

Why it matters. States’ constitutional protections, federal statutes, and other legal disputes remain distinct questions.

Supreme Court · Dobbs docket

Who’s involved

Agency roles and organizational positions are different kinds of information.

FDA / HHSFederal agencies
Regulate medicines and administer federal health and family-planning programs.
State legislatures and medical boardsState authorities
Set many access, licensing, and professional-practice rules.
Planned ParenthoodProvider and advocacy organization
Provides reproductive healthcare and advocates abortion access.
Susan B. Anthony Pro-Life AmericaAdvocacy organization
Advocates abortion restrictions and supports candidates who share that position.

What to watch

Medication litigation and regulation

Read the latest agency requirements and court orders; a standing decision is not a general merits endorsement.

FDA · mifepristone information

How to tell if it’s working. Track maternal health, access to contraception and fertility care, pregnancy support, and the practical effects of access rules. Keep descriptive evidence separate from the moral judgments underlying policy choices.

From the 2028 field

Selected past records, not statements of a 2028 platform. State and federal actions have different scopes.

Explore the field’s documented records →